Quantumzyme Corp. (QTZM) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Quantumzyme Corp. (QTZM) stock?
Quantumzyme Corp. (QTZM) no longer trades on public markets. The figures below are historical and are not a current quote.
Market cap $31.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quantumzyme Corp. (QTZM). Quantumzyme Corp. is a biotransformation company focused on developing engineered enzymes for active pharmaceutical ingredient (API) production. Market cap: $31.2M, Sector: Basic materials.
Last analyzed: Mar 15, 2026Analyst Coverage for QTZM: QTZM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QTZM against Basic Materials peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Quantumzyme Corp. (QTZM) Materials & Commodity Exposure
Quantumzyme Corp., operating in the specialty chemicals sector, focuses on biotransformation by developing engineered enzymes for active pharmaceutical ingredient (API) production. The company aims to improve API manufacturing processes through innovative enzyme technology, targeting the pharmaceutical industry with specialized solutions.
What Is the Investment Thesis for QTZM?
Quantumzyme Corp. presents a focused investment opportunity within the biotransformation sector, specifically targeting the active pharmaceutical ingredient (API) market. The company's core value proposition lies in its ability to develop engineered enzymes that enhance API production efficiency and sustainability. A key growth catalyst is the increasing demand for environmentally friendly and cost-effective API manufacturing processes. Quantumzyme's success hinges on its ability to secure partnerships with pharmaceutical companies and demonstrate the superior performance of its enzymes compared to traditional chemical synthesis methods. The company's high beta of 7.51 indicates significant volatility, reflecting the speculative nature of its early-stage development. The negative P/E ratio of -269.56 suggests that the company is currently unprofitable, requiring investors to focus on future growth potential rather than current earnings.
Based on FMP financials and quantitative analysis
QTZM Key Highlights
Quantumzyme Corp. operates in the biotransformation sector, focusing on engineered enzymes for active pharmaceutical ingredient (API) production.
- The company rebranded from Reliant Services, Inc. to Quantumzyme Corp. in March 2023, signaling a strategic shift.
- Quantumzyme's market capitalization is $31.2M, indicating its small-cap status.
- The company's P/E ratio is -269.56, reflecting its current lack of profitability.
- Quantumzyme has a high beta of 7.51, suggesting significant stock price volatility.
Who Are QTZM's Competitors?
QTZM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALTO Alto Ingredients, Inc. | $3.98 | +0.38% | $308M | 865-pillar |
| FMST Foremost Clean Energy Ltd. | $0.91 | -2.57% | $11.3M | 405-pillar |
| KBSX FST Corp. | $0.98 | +0.05% | $43.9M | — |
| LITM Snow Lake Resources Ltd. | $2.02 | +3.59% | $36.4M | — |
| LOOP Loop Industries, Inc. | $0.44 | +2.53% | $21.3M | — |
| BIOF Blue Biofuels, Inc. | $0.11 | +6.73% | $35.6M | 449-signal |
| KBLB Kraig Biocraft Laboratories, Inc. | $0.08 | +0.69% | $89.0M | 449-signal |
| COOSF Carbios SAS | $6.50 | 0.00% | $110M | 699-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are QTZM's Key Strengths?
Specialized expertise in enzyme engineering.
- Focus on sustainable and efficient API production.
- Potential for proprietary enzyme technologies.
- Strategic partnerships with pharmaceutical companies.
What Are QTZM's Weaknesses?
Limited financial resources.
- Dependence on research and development success.
- Small market capitalization and limited trading volume.
- Negative profitability and high beta.
What Could Drive QTZM Stock Higher?
Potential partnerships with pharmaceutical companies to validate and commercialize enzyme technologies.
- Increasing demand for sustainable and cost-effective API manufacturing processes.
- Development of new proprietary enzyme technologies with patent protection.
- Expansion into emerging markets with growing pharmaceutical industries.
What Are the Key Risks for QTZM?
Competition from larger chemical and biotechnology companies with greater resources.
- Regulatory hurdles and approval processes for new enzyme-based products.
- Technological obsolescence and the emergence of alternative API manufacturing methods.
- Limited financial resources and dependence on research and development success.
- High stock price volatility due to its OTC listing and small market capitalization.
What Are the Growth Opportunities for QTZM?
- Expansion into New API Markets: Quantumzyme can expand its market reach by developing enzymes for a broader range of active pharmaceutical ingredients (APIs). The global API market is projected to reach $274.7 billion by 2030, offering significant growth potential. By targeting specific API segments with unmet needs, Quantumzyme can increase its market share and revenue streams. This expansion requires investment in research and development to create new enzyme solutions and strategic partnerships with pharmaceutical companies to validate and commercialize these innovations. Timeline: 2-3 years.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with major pharmaceutical companies can provide Quantumzyme with access to established distribution channels and increased market visibility. These partnerships can involve joint development projects, licensing agreements, or supply contracts. The pharmaceutical industry is increasingly seeking innovative solutions to improve manufacturing efficiency and sustainability, creating a favorable environment for Quantumzyme's enzyme technology. Successful partnerships can lead to recurring revenue streams and long-term growth. Timeline: Ongoing.
- Development of Proprietary Enzyme Technologies: Investing in research and development to create proprietary enzyme technologies can provide Quantumzyme with a competitive advantage. Patent protection for these technologies can create barriers to entry for competitors and enhance the company's market position. Focus areas include improving enzyme stability, activity, and specificity for various API production processes. Successful development of proprietary technologies can lead to higher profit margins and increased market share. Timeline: 3-5 years.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as India and China, can provide Quantumzyme with access to new customers and growth opportunities. These markets are experiencing rapid growth in the pharmaceutical industry, driven by increasing healthcare spending and a growing population. Establishing a presence in these markets requires understanding local regulations, building relationships with local partners, and adapting products to meet local needs. Successful geographic expansion can significantly increase Quantumzyme's revenue and market share. Timeline: 2-4 years.
- Acquisition of Complementary Technologies or Companies: Acquiring companies with complementary technologies or market access can accelerate Quantumzyme's growth and expand its product portfolio. Potential acquisition targets include companies specializing in enzyme engineering, bioprocessing, or API manufacturing. These acquisitions can provide Quantumzyme with access to new technologies, expertise, and customer relationships. Successful acquisitions require careful integration and strategic alignment to maximize synergies and create long-term value. Timeline: Opportunistic.
What Are QTZM's Competitive Advantages?
- Proprietary enzyme engineering technology.
- Specialized expertise in biotransformation processes.
- Strong relationships with pharmaceutical companies.
- Patent protection for key enzyme innovations.
What Does QTZM Do?
Quantumzyme Corp., established in 2015 and based in San Diego, California, specializes in biotransformation, focusing on the development of engineered enzymes. These enzymes are designed for use in the production of active pharmaceutical ingredients (APIs). The company aims to enhance the efficiency and sustainability of API manufacturing processes through its innovative enzyme technology. Quantumzyme was formerly known as Reliant Services, Inc., and rebranded to Quantumzyme Corp. in March 2023, marking a strategic shift towards its current focus on biotransformation. The company's core business involves the creation and application of enzymes that can catalyze specific chemical reactions, enabling more efficient and environmentally friendly API production. Quantumzyme's products target the pharmaceutical industry, offering specialized solutions to improve manufacturing processes and reduce costs. The company's geographic reach is primarily focused on serving pharmaceutical companies globally, with a focus on markets where API production is prevalent. Quantumzyme competes with other specialty chemical and biotechnology companies that offer enzyme-based solutions for pharmaceutical manufacturing.
What Products and Services Does QTZM Offer?
- Develops engineered enzymes for biotransformation processes.
- Creates enzymes used in the production of active pharmaceutical ingredients (APIs).
- Offers solutions to improve the efficiency and sustainability of API manufacturing.
- Provides specialized enzyme-based solutions for the pharmaceutical industry.
- Focuses on catalyzing specific chemical reactions to enhance API production.
- Aims to reduce costs and environmental impact in pharmaceutical manufacturing.
How Does QTZM Make Money?
- Develops and sells engineered enzymes to pharmaceutical companies.
- Provides customized enzyme solutions for specific API manufacturing processes.
- Generates revenue through enzyme sales and licensing agreements.
- Partners with pharmaceutical companies for joint development projects.
What Industry Does QTZM Operate In?
Quantumzyme Corp. operates within the specialty chemicals industry, specifically targeting the biotransformation segment. The market for engineered enzymes in API production is growing, driven by increasing demand for sustainable and efficient manufacturing processes. The competitive landscape includes companies like ALTO, FMST, KBSX, LITM, and LOOP, which offer various chemical and biotechnology solutions. Quantumzyme differentiates itself through its focus on engineered enzymes tailored for specific API production processes. The industry is characterized by high research and development costs, regulatory scrutiny, and the need for strong partnerships with pharmaceutical companies.
Who Are QTZM's Key Customers?
- Pharmaceutical companies involved in API manufacturing.
- Biopharmaceutical companies seeking to improve production processes.
- Contract manufacturing organizations (CMOs) serving the pharmaceutical industry.
- Generic drug manufacturers looking for cost-effective solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
- ● This is an unknown, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 42 |
| 2026-08-24 | 42 |
| 2026-08-25 | 42 |
| 2026-08-26 | 42 |
What changed?
The score has stayed at 42.
Over the same 3 days the stock moved +0.0%.
Company Profile
Quantumzyme Corp. operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in San Diego, US. The company is led by CEO Naveen Krishnarao Kulkarni. QTZM has traded publicly since 2024.
QTZM Valuation & Market Position
With a $31.2M market cap, Quantumzyme Corp. sits in the micro-cap segment of the market.
Key Financial Metrics
Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -15.8%, the inverse of the P/E and a quick read on earnings relative to price.
QTZM Financials
Bull Case vs Bear Case
Bull Case
- Specialized expertise in enzyme engineering.
- Focus on sustainable and efficient API production.
- Potential for proprietary enzyme technologies.
- Strategic partnerships with pharmaceutical companies.
Bear Case
- Limited financial resources.
- Dependence on research and development success.
- Small market capitalization and limited trading volume.
- Negative profitability and high beta.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QTZM Latest News
No recent news available for QTZM.
Leadership: Naveen Krishnarao Kulkarni
CEO
Naveen Krishnarao Kulkarni is the CEO of Quantumzyme Corp. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in various companies, focusing on research and development, business development, and strategic planning. Kulkarni's expertise lies in driving innovation and commercializing new technologies in the life sciences sector. He holds advanced degrees in biotechnology and business administration.
Track Record: Under Naveen Krishnarao Kulkarni's leadership, Quantumzyme Corp. has focused on developing engineered enzymes for active pharmaceutical ingredient (API) production. He led the company through its rebranding from Reliant Services, Inc. in March 2023, signaling a strategic shift towards biotransformation. His focus has been on securing partnerships and advancing the company's technology platform.
QTZM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quantumzyme Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Company has a registered business address and contact information.
- CEO has a verifiable background and experience.
- Company has a clear business plan and strategy.
- Company has patents or other intellectual property.
- Company has partnerships or collaborations with reputable organizations.
Common Questions About QTZM (Basic Materials)
What happened to Quantumzyme Corp. (QTZM) stock?
Quantumzyme Corp. (QTZM) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy QTZM shares?
No. QTZM stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for QTZM elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before QTZM stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Quantumzyme Corp.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Quantumzyme Corp. do?
Quantumzyme Corp. is a biotransformation company that specializes in developing engineered enzymes for the production of active pharmaceutical ingredients (APIs).
What do analysts say about QTZM stock?
As a small-cap OTC-listed company, QTZM may not have extensive analyst coverage. Investors should focus on the company's fundamentals, such as its technology, partnerships, and market opportunities, to assess its potential. Key valuation metrics to consider include revenue growth, R&D spending, and cash flow.
What are the main risks for QTZM?
Quantumzyme Corp. faces several risks, including competition from larger companies, regulatory hurdles, technological obsolescence, and limited financial resources. As an OTC-listed company, QTZM also carries risks related to liquidity, transparency, and potential price volatility. Investors should carefully evaluate these risks before investing in QTZM.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited.
- OTC market investments carry higher risks.